Core Viewpoint - The acquisition of shares in Yiming Pharmaceutical by Beijing Fuhai marks a significant change in control, with the new actual controller being Yao Jinbo, founder of 58.com, aiming to enhance the company's business development and asset quality [1][3]. Group 1: Share Transfer Details - Beijing Fuhai plans to acquire 43,855,883 shares of Yiming Pharmaceutical from Gao Fan at a price of 15.10 yuan per share, totaling 662 million yuan, which represents 23.00% of the company's total shares [1]. - Following the completion of this transaction, the controlling shareholder will shift from Gao Fan to Beijing Fuhai, with Yao Jinbo becoming the new actual controller [1]. Group 2: Company Performance - Yiming Pharmaceutical has experienced a decline in revenue over the past two years, with projected revenues of 667 million yuan and 652 million yuan for 2023 and 2024, reflecting year-on-year decreases of 22.14% and 2.27% respectively [2]. - The net profit attributable to the parent company for 2023 and 2024 is expected to be 15.39 million yuan and 45.93 million yuan, showing a significant year-on-year change of -65.14% and 198.50% respectively [2]. - In Q1 2025, Yiming Pharmaceutical reported a revenue of 149 million yuan, down 7.41% year-on-year, and a net profit of 18.79 million yuan, down 32.64% year-on-year [2]. Group 3: Performance Commitment - Gao Fan has made performance commitments for Yiming Pharmaceutical, ensuring that the company achieves a minimum revenue of 600 million yuan for each fiscal year from 2025 to 2027, and a net profit of no less than 30 million yuan [2]. - For 2028, the commitments include maintaining positive figures for net profit, total assets, and net assets, along with compliance with specific regulations [2]. Group 4: Market Reaction - Following the announcement of the share transfer, Yiming Pharmaceutical's stock was suspended from trading on May 27, 2025, and upon resuming trading on June 4, it opened at a limit-up price of 13.40 yuan per share, reflecting a 10.02% increase [3].

西藏易明西雅医药科技股份有限公司（以下简称"公司"）全资子公司四 川维奥制药有限公司（以下简称"维奥制药"）近日收到政府补助485.30万 元，占公司2024年度经审计归属于上市公司股东净利润的10.57%。 上述政府补助与公司日常经营活动相关，不具有可持续性。 二、补助的类型及其对公司的影响 根据《企业会计准则第16号-政府补助》的规定，与资产相关的政府补助， 是指企业取得的、用于购建或以其他方式形成长期资产的政府补助；与收益相关 的政府补助，是指除与资产相关的政府补助之外的政府补助。 公司本次获得的政府补助属于与收益相关的政府补助。 证券代码：002826 证券简称：易明医药 公告编号：2025-039 西藏易明西雅医药科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、获取补助的基本情况 上述政府补助预计将增加公司2025年度利润总额485.30万元。 上述数据未经审计，最终的会计处理及对公司损益的影响以年度审计机构 审计结果为准，敬请广大投资者注意投资风险。 三、备查文件 特此公告。 西藏易明西雅医药科技股份有限公司 董事会 二〇二五 ...

Core Viewpoint - The control of Yiming Pharmaceutical (002826.SZ) is changing hands from its founder Gao Fan to Beijing Fuhai, with the new actual controller being Yao Jinbo, marking a significant shift in the company's ownership structure [2][3][8]. Group 1: Ownership Change - Gao Fan signed a share transfer agreement to sell 23% of his shares to Beijing Fuhai at a price of 15.10 yuan per share, totaling 662 million yuan [2]. - Following the announcement, Yiming Pharmaceutical's stock resumed trading and hit the daily limit up, opening at 13.40 yuan per share [2]. - The new controller, Yao Jinbo, is also the chairman and CEO of 58.com and holds a significant stake in Kuaigou Dache [3][4]. Group 2: Financial Commitments - The share transfer agreement includes performance commitments, with a revenue target of no less than 600 million yuan annually from 2025 to 2027, and a net profit target of at least 30 million yuan for the same period [8]. - If performance targets are not met, Gao Fan will provide compensation based on specific conditions outlined in the agreement [8]. Group 3: Company Performance - Yiming Pharmaceutical's revenue for 2022, 2023, and projected 2024 are 857 million yuan, 667 million yuan, and 652 million yuan respectively, with net profits of 44 million yuan, 15 million yuan, and 46 million yuan [9]. - The company has shown a decline in revenue and profitability, with a significant reliance on its diabetes drug, Miglitol, which generated 474 million yuan in 2024, accounting for 72.72% of total revenue [9]. - The cardiovascular product, Guo Loupian injection, has seen a drastic revenue drop of 55.61% in 2024, leading to the termination of its partnership with Shanghai Pharmaceutical Group [9][10].

证券代码：002826 证券简称：易明医药 公告编号：2025-039 西藏易明西雅医药科技股份有限公司 关于子公司获得政府补助的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、获取补助的基本情况 西藏易明西雅医药科技股份有限公司（以下简称"公司"）全资子公司四 川维奥制药有限公司（以下简称"维奥制药"）近日收到政府补助485.30万 元，占公司2024年度经审计归属于上市公司股东净利润的10.57%。 上述政府补助与公司日常经营活动相关，不具有可持续性。 二、补助的类型及其对公司的影响 1、补助的类型 根据《企业会计准则第16号-政府补助》的规定，与资产相关的政府补助， 是指企业取得的、用于购建或以其他方式形成长期资产的政府补助；与收益相关 的政府补助，是指除与资产相关的政府补助之外的政府补助。 2、补助的确认、计量 根据《企业会计准则第16号——政府补助》的规定，公司收到与收益相关 的政府补助时，与企业日常活动相关的政府补助，按照经济业务实质，计入其 他收益或冲减相关成本费用，与企业日常活动无关的政府补助，计入营业外收 入。 本次公司收到485. ...

买家涉及产业方、国资、私募股权投资机构等。 又有上市公司控制权被收购。这次是58同城创始人姚劲波拟以6.62亿元收购易明医药（002826.SZ）控 制权。6月4日开盘，易明医药一字涨停。 6月3日晚间，易明医药公告称，姚劲波实控的企业拟收购易明医药23%股权，收购价格为15.10元/股， 相较停牌前的收盘价12.18元/股，溢价约24%。收购完成后，易明医药实际控制人将由高帆变更为姚劲 波。近年来该公司业绩承压，存在依赖单一产品的风险。 同日晚间，菲林格尔（603226.SH）也公告控制权拟发生变更。该公司实际控制人丁福如及其一致行动 人、大股东菲林格尔控股有限公司拟分别出让上市公司25%、27.22%的股权，交易完成后，实控人发生 变更。受让方为产业资本、国有信托和私募基金。 今年以来，有较多上市公司披露了控制权拟变更的公告，买家涉及产业方、国资、私募股权投资机构 等，有些则是国资+产业方、国资+GP等组合架构。 姚劲波拟6.6亿收购易明医药控制权 根据公告，北京福好、北京福雅均成立于2025年3月份，为此次权益变动专门设立，均尚未开展实际经 营活动，也暂无改变或调整上市公司主营业务的计划。 对此，买卖双 ...

Core Viewpoint - The acquisition of Yiming Pharmaceutical by Beijing Fuhao has led to a significant increase in the company's stock price, with a closing price of 13.4 yuan per share, marking a 10.02% rise and a total market value of 2.555 billion yuan [2]. Group 1: Acquisition Details - Beijing Fuhao signed a share transfer agreement with the controlling shareholder Gao Fan to acquire 43.8559 million shares of Yiming Pharmaceutical, representing 23% of the total shares, at a price of 15.1 yuan per share, totaling 662 million yuan [2]. - The acquisition price reflects a premium of 23.97% over the closing price of 12.18 yuan per share on the trading day prior to the agreement [2]. - Beijing Fuhao was established specifically for this transaction and has not yet commenced actual business operations [2]. Group 2: New Leadership - The new controlling shareholder, Yao Jinbo, is the founder of 58.com and has significant experience in various sectors, including life services, finance, and advanced manufacturing [4][5]. - The change in control is expected to bring new management ideas, funding support, and opportunities in new markets for Yiming Pharmaceutical [6]. Group 3: Performance Commitments - The share transfer agreement includes performance commitments, with the seller promising that the existing business will achieve audited net profits of no less than 30 million yuan from 2025 to 2027 [8]. - Yiming Pharmaceutical's main revenue sources include diabetes and cardiovascular drugs, with a significant contribution expected from the α-glucosidase inhibitor Miglitol tablets [8]. - The company reported a decline in revenue and net profit in the first quarter of the year, with a total revenue of approximately 149 million yuan, down 7.41% year-on-year, and a net profit of approximately 18.79 million yuan, down 32.64% year-on-year [9].

Group 1 - The core point of the news is that Beijing Fuhao Enterprise Management Partnership is acquiring a 23% stake in Yiming Pharmaceutical from its controlling shareholder, Gao Fan, at a price of 15.1 yuan per share, totaling 662 million yuan [1] - After the completion of this equity change, the controlling shareholder will shift from Gao Fan to Beijing Fuhao, and the actual controller will change from Gao Fan to Yao Jinbo [1] - Yiming Pharmaceutical primarily engages in the research, production, and sales of chemical drugs and traditional Chinese medicine, focusing on products for chronic diseases such as diabetes and cardiovascular diseases [1] Group 2 - In terms of financial performance, Yiming Pharmaceutical reported a total revenue of 652 million yuan for the year 2024, a decrease of 2.27% year-on-year, while net profit attributed to shareholders was 46 million yuan, showing a significant increase of 198.50% [2] - Despite the impressive net profit growth, the company's revenue has declined for the second consecutive year, with a revenue of 667 million yuan in 2023, down 22.14% year-on-year, indicating significant competitive pressure in the market [2] Group 3 - Yao Jinbo, the new actual controller, is the founder of 58 Group, which has completed various capital operations and has a diverse business portfolio covering real estate, automotive, recruitment, finance, and local services [4] - Yao Jinbo's companies under his control have an annual revenue exceeding 1.5 billion yuan, indicating a strong financial background and potential for strategic growth [4] - Yiming Pharmaceutical's stock price increased by 10.20% today, reaching 13.40 yuan per share, reflecting positive market sentiment following the announcement [5]

登录新浪财经APP 搜索【信披】查看更多考评等级 中国经济网北京6月4日讯 易明医药(002826.SZ)今日复牌，开盘后一字涨停，截至发稿报13.40元，涨幅 10.02%，总市值25.55亿元。 昨日晚间，易明医药发布关于筹划公司控制权变更事项进展暨公司股票复牌的公告。公司控股股东、实 际控制人高帆因筹划控制权变更事宜，为保证公平信息披露，避免公司股价异常波动，维护广大投资者 利益，根据《深圳证券交易所股票上市规则》及《深圳证券交易所上市公司自律监管指引第6号——停 复牌》的规定，公司向深圳证券交易所申请自2025年5月27日（星期二）开市起停牌。 为保证公司股票的流通性，维护广大投资者利益，根据《深圳证券交易所股票上市规则》《深圳证券交 易所上市公司自律监管指引第6号——停复牌》等有关规定，经公司申请，公司股票（证券简称：易明 医药，证券代码：002826）自2025年6月4日（星期三）开市起复牌。 昨日晚间，易明医药发布关于控股股东、实际控制人签署《股份转让协议》暨公司控制权拟发生变更的 提示性公告。2025年5月31日，北京福好企业管理合伙企业（有限合伙）（以下简称"北京福好"）与上 市公司控股股东 ...

深圳商报·读创客户端记者 穆砚 此前，易明医药两度披露关于筹划公司控制权变更进展暨延期复牌的公告。 公开资料显示，西藏易明西雅医药科技股份有限公司于2016年12月9日上市，主要从事化学药以及中成 药的研发、生产和销售。公司主要产品为米格列醇片、醋氯芬酸肠溶片、红金消结片、蒙脱石散、多潘 立酮片、阿奇霉素胶囊、氯雷他定片、第三方合作药品。 纵观近年业绩，易明医药净利如坐"过山车"，2023年下滑超六成，在2024年大幅回暖后今年首季度再次 减少。2022年至2024年，公司归母净利润为0.44亿元、0.15亿元、0.46亿元。 对于去年业绩同比上升，易明医药表示，公司上年同期计提商誉减值1980万元，本报告期经初步测试无 商誉减值事项，资产减值损失较上年同期减少1980万元。此外，本报告期收到2023年度产业扶持专项资 金2819万元，公司于实际收到款项的当月计入2024年其他收益，较上年同期增加1627万元。此为非经常 性损益。 2025年第一季度，易明医药营业收入为1.49亿元，同比减少7.41%；归母净利润1879.39万元，同比减少 32.64%；经营性现金流为3086.59万元，同比下降42.56% ...

湘财证券股份有限公司 关于西藏易明西雅医药科技股份有限公司 详式权益变动报告书 之 财务顾问核查意见 财务顾问 二〇二五年六月 （六）本财务顾问特别提醒投资者认真阅读信息披露义务人出具的详式权益 变动报告书以及相关公告全文、备查文件； 声 明 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司收购 管理办法》《公开发行证券的公司信息披露内容与格式准则第15号——权益变动 报告书》《公开发行证券的公司信息披露内容与格式准则第16号——上市公司收 购报告书》及相关法律、法规的规定，湘财证券股份有限公司（以下简称"本财 务顾问"）就信息披露义务人披露的《西藏易明西雅医药科技股份有限公司详式 权益变动报告书》进行了核查，并出具本财务顾问核查意见。 本财务顾问是按照行业公认的业务标准、道德规范和诚实信用、勤勉尽责的 精神，本着独立、客观、公正的原则，在认真审阅相关资料和充分了解本次权益 变动的基础上，发表财务顾问意见，旨在就本次权益变动作出独立、客观和公正 的评价，以供广大投资者及有关各方参考。本财务顾问特作如下声明： （一）本财务顾问意见所依据的文件、材料由信息披露义务人提供。有关资 料提供方已对本财务顾 ...